(UroToday.com) The Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Think Tank 2025, held in Washington D.C., United States, was host to the session: BCAN 2023 Bladder Cancer Research Innovation ...

Dr. Lerner opened his presentation by discussing the SWOG S1011 trial, a randomized clinical study evaluating the benefit of limited versus extended pelvic lymph node dissection at the time of radical ...

Dr. Jonathan Rosenberg discussed the CALGB 90601 study and titled his talk: From lemons to lemonade, possibilities from negative cooperative group trials. Dr. Rosenberg began by highlighting one of ...

Women who complain of bladder pain and urinary urgency and frequency wait years to receive the label of interstitial cystitis (IC), an "orphan disease" which has no known cause or cure. The current ...

ASCO GU 2025 lead-in phase results of the ARAMON trial assessing darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

ASCO 2025 HIF-2α targeting as a new frontier in renal cell cancer (RCC) therapy, Von Hippel-Lindau (VHL) gene mutation, LITESPARK-005, metastatic clear cell RCC. belzutifan.

UroToday's exclusive Video Lecture content covering mCRPC Treatment.

SNMMI 2025, post-177Lu therapy, WB SPECT/CT, WB SPECT/CT Studies Post Lu 177 Therapy, 177Lu-PSMA SPECT, StarGuide scanner, 177Lu-PSMA-617 radiopharmaceutical therapy.

AUA 2025 thermal safety of high-powered lasers during endoscopic stone surgery, renal calyceal, parenchymal temperatures, laser lithotripsy, 60W Super-Pulse Thulium Fiber Laser (TFL), 120W ...

ASCO 2025 BULLSEYE trial, Prostate-Specific Membrane Antigen (PSMA) Radioligand Therapy, androgen deprivation therapy (ADT), 177Lu-PSMA-617, PSMAddition.

Stone Disease Urinary Retention research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.